Disease diagnostics involves
various laboratory techniques for identification of test samples such as blood
and urine for identification and quantification of infective agents. Providing
diagnosis based only on symptoms is challenging, as two or more diseases can
exhibit similar symptoms and therefore diagnostic tests are used for
confirmation of the disease. Diagnostic tests provide rapid and precise
results, thereby saving time and providing physicians ample time for treatment.
The global Infectious
Disease Diagnostics Market is estimated to account for US$ 1,131.4 Mn in
terms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of
2027.
Global Infectious Disease
Diagnostics Market: Drivers
Initiatives to address diagnostic
challenges in emerging economies is expected to propel growth of the global
infectious disease diagnostics market over the forecast period. For instance,
in January 2018, The Foundation for Innovative New Diagnostics collaborated
with Becton, Dickinson, and Company (BD), Fondation Botnar, the Global
Antibiotic Research & Development Partnership (GARDP), the Drugs for
Neglected Diseases Initiative (DNDi), and the South African Medical Research
Council (SAMRC) to address antimicrobial resistance (AMR) by accelerating the
use of diagnostics.
Global Infectious Disease Diagnostics
Market: Opportunities
Public and private initiatives to
curb infectious diseases is expected to offer lucrative growth opportunities
for players in the market. For instance, in February 2020, Department of Health
and Human Services announced a federal grant of US$ 750,000 to the city of
Austin to help fight the spread of HIV/AIDS in Texas, U.S.
Global Infectious Disease
Diagnostics Market: Restraints
Low awareness and adoption of
diagnostic services in emerging economies is expected to hinder growth of the
market. For instance, according to GLOBAL AIDS UPDATE 2019 of UNAIDS, in
Madagascar, Mauritius, and South Sudan, fewer than 25% of people living with
HIV are aware of their status.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1971
Key Takeaways:
The cell cultures segment in the
global infectious disease diagnostics market was valued at US$ 362.3 Mn in 2018
and is expected to reach US$ 747.4 Mn by 2027 at a CAGR of 8.3% during the
forecast period. Several types of infections can be diagnosed using cell
culture, where, microbes are grown in a laboratory setting to identify the
same.
The STDs segment held dominant
position in the global infectious disease diagnostics market in 2018,
accounting for 32.8% share in terms of value, followed by CNS infection, and
respiratory infections, respectively. Increasing sexually transmitted disease
burden is fueling growth of the segment. Among 20 STDs, the most common are
Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human
Immunodeficiency Virus (HIV). For instance, according to Centers for Disease
Control and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydia
trachomatis infection were reported in the U.S., corresponding to 497.3 cases
per 100,000 in 2015.
Diagnostic centers segment in the
global infectious disease diagnostics market was valued at US$ 462.1 Mn in 2018
and is expected to reach US$ 958.7 Mn by 2027 at a CAGR of 8.5% during the
forecast period. Central diagnostic laboratories are well equipped with latest
diagnostic instruments, and have large resources to carry out multiple tests.
Large number of tests are carried out on a daily basis in these centers which supports
growth of the segment.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/infectious-disease-diagnostics-market-1971
Market Trends
Limited specificity of diagnostic
tests available for infectious diseases triggers the need for combined
diagnosis, which includes multiple tests. The trend of diagnosing a disease
through multiple tests is gaining popularity.
The market in North America is
expected to witness significant growth, owing to increasing healthcare
expenditure. For instance, according to the Centers for Medicare & Medicaid
Services (CMS), health spending in the U.S. is projected to grow at an average
rate of 5.5 percent per year for 2018-27 and to reach nearly US$ 6.0 trillion
by 2027. However, the reimbursement scenario for diagnostic tests is
comparatively poorer.
Global Infectious Disease
Diagnostics Market: Competitive Landscape
Major players operating in the
global infectious disease diagnostics market include, Becton Dickinson &
Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc.,
Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Alera
Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
Global Infectious Disease Diagnostics
Market: Key Developments
March 2020: Chembio Diagnostics,
Inc., a point-of-care diagnostics company focused on infectious diseases,
completed the technical feasibility phase for a potential companion/compatible
diagnostic test being developed in collaboration with Shire Human Genetic
Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company
Limited
March 2020: GenMark Diagnostics,
Inc., a provider of automated, multiplex molecular diagnostic testing systems,
submitted an Emergency Use Authorization to the U.S. Food and Drug
Administration (FDA) for its ePlex SARS-CoV-2 Test
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1971
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment